Comjoyful International Co. (KJFI)

[levelnever]

So please stop me if I've talked before about Ruhi Kahn, Jeffrey Rochlin's boss at Acorda, but I think the steps she has taken may be related to what is going on. If the CAML acquisition has anything to do with Acorda, she is the key person in this whole equation IMO.

Just a little background:

She was the one responsible for setting up the partnership with Biogen IDEC to commercialize fampridine outside the US market. She is also the main person responsible for any and all strategic initiatives for Acorda Therapeutics.

http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol-newsArticle&ID=1303770&highlight=.

And this from her bio:

Before joining the Company, Ms. Khan was the Senior Director of Business Development at Lexicon Pharmaceuticals. While at Lexicon, she led the business development function for both in-licensing and out-licensing of programs, research stage collaborations, technology assessments, spin-outs and other strategic initiatives.

I will keep researching her as time allows, but as much as we are looking at Jeffrey Rochlin, I think, if we believe this has something to do with Acorda, we should look at Ruhi Kahn as well.